Nobivac Parvo-C

Valsts: Īrija

Valoda: angļu

Klimata pārmaiņas: HPRA (Health Products Regulatory Authority)

Aktīvā sastāvdaļa:

Canine parvovirus attenuated strain 154

Pieejams no:

Intervet Ireland Limited

ATĶ kods:

QI07AD01

SNN (starptautisko nepatentēto nosaukumu):

Canine parvovirus attenuated strain 154

Deva:

.

Zāļu forma:

Lyophilisate and solvent for suspension for injection

Receptes veids:

POM: Prescription Only Medicine as defined in relevant national legislation

Ārstniecības grupa:

Dogs

Ārstniecības joma:

canine parvovirus

Ārstēšanas norādes:

Immunological - Live Vaccine

Autorizācija statuss:

Authorised

Autorizācija datums:

2004-03-05

Produkta apraksts

Health Products Regulatory Authority
14 October 2021
CRN00CCQ2
Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Nobivac Parvo-C
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each single dose of the vaccine vial contains:
_Active Ingredients:_
Canine parvovirus (strain 154) not less than 10
7.0
TCID
50
*
*Tissue culture infective dose 50%
_Excipients: _
For a full list of excipients see 6.1
_Solvent (1ml per vial):_
Phosphate buffered saline.
3 PHARMACEUTICAL FORM
Lyophilisate and solvent for suspension for injection.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs.
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For active immunisation of dogs to prevent clinical signs of disease
and excretion of virulent canine parvovirus caused by
canine parvovirus infection. Onset of immunity has been shown to occur
from 1 week after dosing and last for up to 3 years.
4.3 CONTRAINDICATIONS
None.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
The efficacy of the vaccine may be reduced due to maternal antibody
interference. However, the vaccine has been proven to be
of benefit against virulent challenge in the presence of maternal
antibody levels that are likely to be encountered under field
conditions.
4.5 SPECIAL PRECAUTIONS FOR USE
_Special precautions for use in animals_
Only healthy dogs should be vaccinated. Dogs should not be exposed to
unnecessary risk of infection within the first week
after vaccination.
While the canine parvovirus vaccine strain may be shed at very low
levels for up to 8 days after inoculation, there is no
evidence that this results in clinical symptoms if non-vaccinated
animals are infected.
_Special precautions to be taken by the person administering the
veterinary medicinal product to animals_
In the case of accidental self-injection, wash the area immediately
with water. If symptoms develop, seek medical advice
immediately and show the package leaflet or the label to the
physician.
Health Products Regulatory Authority
14 October 2021
CRN00CCQ2
Page 2 of 4
4